Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview
MAPK forms the backbone of four primary signal transduction cascades leading to the phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK1--2), JNK, p38 and ERK5. MAPK kinases 1 and 2, commonly known at MEK1--2, are referred to as MEK. Because of their importance in cell proliferation and signaling, MAPK pathways are being targeted for new drugs for oncology, inflammation and other conditions. Several inhibitors of MEK1--2 (MAPK kinases 1 and 2) are nearing, or are currently in, clinical trials for oncology.
MEK1 and 2 are downstream of genes frequently mutated in tumors (such as EGFR, RAS and RAF), and in preclinical models, MEK inhibitors have demonstrated potent antitumor activity. MEK inhibitors have shown objective responses when used as monotherapy, particularly in tumors with known BRAF-activating mutations.
Report Highlights
This segment of the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Emerging Drugs
Koselugo was granted US FDA Breakthrough Therapy Designation in April 2019, Rare Pediatric Disease Designation in December 2019, Orphan Drug Designation in February 2018, EU orphan designation in August 2018 and Swissmedic Orphan Drug Status in December 2018 for the treatment of paediatric patients with NF1 PN.
Further product details are provided in the report……..
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs.
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview
MAPK forms the backbone of four primary signal transduction cascades leading to the phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK1--2), JNK, p38 and ERK5. MAPK kinases 1 and 2, commonly known at MEK1--2, are referred to as MEK. Because of their importance in cell proliferation and signaling, MAPK pathways are being targeted for new drugs for oncology, inflammation and other conditions. Several inhibitors of MEK1--2 (MAPK kinases 1 and 2) are nearing, or are currently in, clinical trials for oncology.
MEK1 and 2 are downstream of genes frequently mutated in tumors (such as EGFR, RAS and RAF), and in preclinical models, MEK inhibitors have demonstrated potent antitumor activity. MEK inhibitors have shown objective responses when used as monotherapy, particularly in tumors with known BRAF-activating mutations.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors R&D. The therapies under development are focused on novel approaches for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors.
This segment of the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Emerging Drugs
- Selumetinib - AstraZeneca
Koselugo was granted US FDA Breakthrough Therapy Designation in April 2019, Rare Pediatric Disease Designation in December 2019, Orphan Drug Designation in February 2018, EU orphan designation in August 2018 and Swissmedic Orphan Drug Status in December 2018 for the treatment of paediatric patients with NF1 PN.
Further product details are provided in the report……..
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs.
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Report Insights
- Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs?
- How many Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- CStone Pharmaceuticals
- AUM Biosciences
- Novartis
- Array BioPharma
- Chongqing Fochon Pharmaceutical
- Selumetinib
- CS 3006
- AUM 001
- Trametinib
- Binimetinib
- FCN 159
Introduction
Executive Summary
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Selumetinib- AstraZeneca
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Trametinib - Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CS 3006: CStone Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
FCN 159: Chongqing Fochon Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Companies
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Products
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Unmet Needs
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Market Drivers and Barriers
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Future Perspectives and Conclusion
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Analyst Views
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Companies
Appendix
Executive Summary
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Selumetinib- AstraZeneca
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Trametinib - Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CS 3006: CStone Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
FCN 159: Chongqing Fochon Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Companies
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Products
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Unmet Needs
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Market Drivers and Barriers
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Future Perspectives and Conclusion
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Analyst Views
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
